These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8886906)

  • 1. Intravesical therapy of bladder cancer: an immunotherapy success story.
    Morales A
    Int J Urol; 1996 Sep; 3(5):329-33. PubMed ID: 8886906
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy of bladder cancer.
    Nseyo UO; Lamm DL
    Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 6. BCG vaccine in urinary bladder cancer.
    Brosman SA
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG in management of transitional cell carcinoma invasive to prostate.
    Siami P; Chinn S; Clayton M; Ray V; Rubenstein M; Guinan P
    Urology; 1989 Dec; 34(6):381-2. PubMed ID: 2595884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
    Lamm DL; Griffith JG
    Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin therapy for high-risk superficial bladder cancer.
    Thanos A; Karassantes T; Davillas E; Sotiriou V; Davillas N
    Scand J Urol Nephrol; 1994 Dec; 28(4):365-8. PubMed ID: 7886412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T1G3: What to do?
    Mandressi A
    Arch Ital Urol Androl; 1996 Feb; 68(1):5-7. PubMed ID: 8664922
    [No Abstract]   [Full Text] [Related]  

  • 14. Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.
    Torti FM; Lum BL
    Cancer; 1987 Feb; 59(3 Suppl):613-6. PubMed ID: 2433019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

  • 16. The management of stage T1 grade 3 transitional cell carcinoma of the bladder.
    Evans CP; Busby JE
    BJU Int; 2003 Sep; 92(4):345-8. PubMed ID: 12930415
    [No Abstract]   [Full Text] [Related]  

  • 17. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 20. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.